Article Text

PDF

SP0093 Junctional adhesion molecule-2 (jam-2) is localised at intercellular junctions and plays a role in lymphocyte transmigration
  1. B Imhof,
  2. CA Johnson-Léger,
  3. M Aurrand-Lions,
  4. C Wong
  1. Of Pathology, Centre Médical Universitaire, Geneva 4, Switzerland

Abstract

We identified a novel Junctional Adhesion Molecule by a selective RNA display method. The protein was named JAM-2 based on its 30–40% homology to JAM and VE-JAM. The three JAMs define a novel subset of immunoglobulin superfamily molecules which will be referred to as JAM-1 (JAM), JAM-2 and JAM-3 (VE-JAM). JAM-2 is highly expressed by HEVs and lymphatic endothelial cells in lymphoid organs, suggesting that it may play a role in lymphocyte recirculation. The role of JAM-2 in inter-endothelial junctions has been addressed using endothelial cells over-expressing JAM-2 protein. These cells have an increased ability to sustain lymphocyte transmigration in agreement with the pattern of expression found in vivo. Transfected cells are also more permeable to FITC-dextran. Furthermore, an antibody directed against the extracellular domain of JAM-2 is able to partially block the transmigration. Our findings suggest that JAM-2 may facilitate lymphocyte extravasation across HEVs by rendering the inter-endothelial junctions more leaky. The role of JAM-2 in inflammatory processes will be discussed.

Reference

  1. Aurrand-Lions M, Duncan L, Ballestrem C, Imhof BA. JAM-2, a novel immunoglobulin superfamily molecule, expressed by endothelial and lymphatic cells. J Biol Chem. 2001;276:2733–41

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.